Replies to post #193110 on Biotech Values

[DewDiligence]

AGTC CC notes:

• AGTC’s two programs (B3/A3) in achromatopsia are not part of the BIIB collaboration.

• After deal consummation, BIIB will own an 8.1% equity stake in AGTC.

[DewDiligence]

AGTC earns $5M milestone from BIIB for enrollment threshold in XLRS phase-1/2 trial:

http://finance.yahoo.com/news/agtc-announces-achievement-xlrs-patient-110000082.html

[DewDiligence]

BIIB dumps AGTC collaboration on five gene-therapy programs:

https://globenewswire.com/news-release/2018/12/12/1666252/0/en/AGTC-Announces-Topline-Interim-Six-Month-Data-from-Phase-1-2-X-Linked-Retinoschisis-Clinical-Study-Termination-of-Biogen-Collaboration.html

The collaboration was inked in 2015 (#msg-115114540); AGTC received $124M up-front (including $30M from an equity sale), but earned only $5M of milestone payments since then.

AGTC CC at 5pm ET.